Optimizing Hepatitis B Vaccination in HIV Patients with Suboptimal Immune Response

HIV patients who receive a standard 3-dose hepatitis B vaccine series using an aluminum hydroxide-adjuvanted vaccine—either Engerix-B or Recombivax HB—may fail to develop adequate protective immunity, defined as a hepatitis B surface antibody titer of at least 10 milli-international units per mL, David Ha, PharmD, lecturer of medicine at Stanford University School of Medicine, said. This suboptimal response is well-documented in populations with diminished immune function, including those with HIV, chronic kidney disease, immunocompromise, or those on hemodialysis. In these higher-risk groups, post-vaccination antibody titer testing is an important step to confirm immunity has been established.

For patients in these populations who do not achieve adequate immunity following the standard series, revaccination with Heplisav-B is the preferred approach. Its cytosine guanine adjuvant makes it substantially more immunogenic than the older aluminum-adjuvanted formulations, particularly in patients less likely to respond to conventional vaccines. At minimum, a 2-dose Heplisav-B series administered at 0 and 1 month is recommended, followed by repeat titer testing to confirm immune response. Emerging data in HIV patients suggests that a 3-dose series—given at 0, 1, and 6 months—may produce even stronger immunity and can be considered for patients who still do not mount an adequate response after the initial 2 doses.